



Humanizing recombinant glycoproteins from Chinese hamster ovary cells

Hansen, Anders Holmgaard; Amann, Thomas; Kol, Stefan; Kildegaard, Helene Fastrup

Publication date:
2017

Document Version
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

Citation (APA):

Hansen, A. H., Amann, T., Kol, S., & Kildegaard, H. F. (2017). *Humanizing recombinant glycoproteins from Chinese hamster ovary cells*. Abstract from 19th European Carbohydrate Symposium, Barcelona, Spain.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



Humanizing recombinant glycoproteins from Chinese hamster ovary cells

Anders Holmgaard Hansen¹, Thomas Amann¹, Stefan Kol¹, Helene Faustrup Kildegaard¹

¹ Novo Nordisk Foundation Center for Biosustainability. Technical University of Denmark. Lyngby.
e-mail: ahoha@biosustain.dtu.dk

With new tools for gene-editing like zinc-fingers, TALENS and CRISPR[1], it is now feasible to tailor-make[2] the N-Glycoforms for therapeutic glycoproteins that have previously been almost impossible. We here demonstrate a case of humanizing a recombinant human glycoprotein that in Wild type (WT) Chinese hamster ovary (CHO) cells are making a very heterogeneous mixture of N-Glycans (see Figure 1). We speculate that the CHO pattern of N-Glycans would affect half-life and/or efficacy of the glycoprotein in the bloodstream making it unsuitable for human intravenous use, whereas our humanized version would be identical to the native human glycoprotein.




Figure 1. Fluorescence trace from LC-MS run of RapiFlour labelled N-Glycans, released from purified glycoprotein. Heterogeneous N-Glycans from glycoprotein produced in CHO-WT (A). Glycoprotein produced in CHO-KO strain produces a much more homogenous pattern of N-Glycans (B). The N-Glycan pattern target for this work; N-Glycan pattern of Human plasma glycoprotein (C).

[1] Grav, L. M.; Lee, J. S.; Gerling, S.; Kallehauge, T. B.; Hansen, A. H.; Kol, S.; Lee, G. M.; Pedersen, L. E.; Kildegaard, H. F. *Biotechnol. J.* 2015, 10 (9), 1446.

[2] (1) Yang, Z.; Wang, S.; Halim, A.; Schulz, M. A.; Frodin, M.; Rahman, S. H.; Vester-Christensen, M. B.; Behrens, C.; Kristensen, C.; Vakhrushev, S. Y.; Bennett, E. P.; Wandall, H. H.; Clausen, H. *Nat. Biotechnol.* 2015, No. October 2014, 2014.